Introduction
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are potent inhibitors of cholesterol biosynthesis. Large-scale clinical trials have demonstrated significant reductions in cardiovascular events following statin therapy (1) (2) (3) (4) (5) . The observed benefit of statin therapy, however, may be larger in these trials than might be expected from lowering lipid levels alone (6) . Recently, many effects other than cholesterol lowering of statins have been reported . In addition to a lipid-lowering effect, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have an effect on the expression levels of many genes. In order to elucidate the range of this effect as comprehensively as possible, we investigated the changes in gene expression profiles brought about by atorvastatin or pitavastatin in cultured human umbilical vein endothelial cells (HUVEC), cultured human coronary artery smooth muscle cells (HCASMC) and cultured human hepatocarcinoma Hep G2 cells by means of DNA microarrays. Among the 6146 genes in the array, statins affected the expression levels of genes involved in coagulation, vascular constriction and cell growth in a cell-type specific manner. In HUVEC, they induced integrin β4 and thrombomodulin profoundly, and profoundly suppressed pentraxin 3 both at 8 and 24 hours. In HCASMC, the statins induced thrombomodulin and urokinase inhibitor, and potently suppressed the cysteine-rich angiogenic inducer 61 and cyclin B. Many genes related to the cell cycle and/or growth were also regulated in HUVEC and HCASMC by the statins. These results indicate that many aspects of the pleiotropic effect can be mediated by transcriptional control by statins. Genes newly identified by this study may be useful in statin therapy. J Atheroscler Thromb, 2004; 11: 62-72.
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Expression of many genes important for vascular function are known to be affected by statins, and comprehensive analysis of the effect on gene expression level may provide previously unknown targets for statin therapy. DNA microarray analysis is suitable for comprehensive analysis at the transcriptional level in vascular cells (32) (33) (34) (35) . Since statins are known to affect the genes related to vascular function, a comparison of their effect on vascular wall cells and other cell types may be important. We determined the effect using cultured human cells, including a human umbilical vein endothelial cell (HUVEC), a human coronary artery smooth muscle cell (HCASMC) and a hepatocellular carcinoma cell line, Hep G2 cell, in order to compare the cell-type specific effect of statins. We have previously reported that among various statins pitavastatin (NK-104) ((+)-monocalcium bis {(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate}) was able to induce LDL receptor mRNA most effectively (36) . In this study we studied the RNA expression profile in the presence of pitavastatin and atrovastatin (10) , which is one of the most potent clinically used statins. From the results of a previous time course study (36) , we determined the gene expression level at 8 hours and 24 hours after the addition of statins.
Here we report the results of comprehensive profiling of RNA expression in these cells. The original DNA chip results can be downloaded from our website (www.lsbm.org) as an Excel format file.
Materials and Methods
Cells and cell culture
Human umbilical vein endothelial cells (HUVEC) were obtained from a commercial source (Clonetics, San Diego, CA USA Lot No.9F1034) and were grown in endothelial cell growth factor containing medium-2 (EGM2, Clonetics) with 2% fetal bovine serum (FBS) at 37°C in a 5% CO2 atmosphere. Human coronary artery smooth muscle cells (HCASMC) were obtained from a commercial source (Cell applications, Inc., San Diego, CA Lot No.1347) and were grown in smooth muscle cell basal medium-2 (SmBM-2, Clonetics) with smooth muscle cell growth supplement containing 2% fetal bovine serum (FBS) at 37°C in a 5% CO2 atmosphere. Human hepatoma HepG2 cells (American Type Culture Collection, Rockville, Maryland, USA) were maintained in Dulbecco's modified eagle's medium (DMEM, Sigma) with 10% fetal bovine serum (FBS) at 37°C in a 5% CO2 atmosphere.
The cells were plated at a density of 3 × 10 5 cells in a 100 mm dish and incubated 48 hours in the same medium. 1.1 µM of pitavastatin and 6.6 µM of atorvastatin were added to the medium. Pitavastatin and atorvastatin were dissolved in dimethylsulfoxide (DMSO, SIGMA, St. Louis, MO USA). The control cells were cultured in each medium containing 0.01% DMSO in the absence of statins. Eight or 24 hours later, the cells were harvested and the mRNA was recovered and analyzed as described in our previous papers (33) (34) (35) (36) .
Reverse transcription-polymerase chain reaction
The total RNA was isolated from HUVEC, HCASMC and HepG2 with ISOGEN (Nippongene, Tokyo, Japan A T G C A G A T G T C T C C A G C C C T C 96 -3 ' a n d 5 ' CCGTTCAGCTCAGGGATGACCT 716 -3'). Polymerase chain reaction amplification used the following conditions: denaturation for 1 minute at 95°C, annealing for 1 minute at 57°C, and elongation for 1 minute at 72°C for 25 cycles. In case of TM, it was denaturation for 1 minute at 95°C, annealing for 1 minute at 60°C, and elongation for 1 minute at 72°C for 35 cycles using GC buffer (Takara, Ohtsu, Japan). When total RNA between 0.05 to 0.4 µg was used for the assay, the linearity of the assay was confirmed.
Results
Global analysis of gene expression profile during statin treatment in cultured human cells (1) HUVEC Table 1 column A and B indicates the top 5 genes most profoundly suppressed by statin treatment in HUVEC. Pentraxin 3 (PTX3), cysteine-rich angiogenic inducer 61 (Cyr61), and monocyte chemotactic protein-1 (MCP1) are reduced more than 3 fold both at 8 and 24 hours by both statins. PTX3 has recently been recognized as an important indicator of the severity of myocardial infarction (37) . PTX3 is known to be expressed in atherosclerotic lesions and can induce tissue factor expression (38, 39) . The reduction of the PTX3 mRNA level may be related to the clinical effect of statin. In order to confirm the suppression of PTX3 expression, the level was studied by RT-PCR (Lower panel of Fig. 1 ). Pitavastatin suppressed the PTX3 mRNA level in a dose-dependent manner. PTX3 expression is also suppressed in HCASMC by both statins.
The expression of Cry61 gene (40) was also suppressed at 8 and 24 hours by both statin treatments. Expression of MCP1, a chemokine which plays an important role in atherogenesis, is also suppressed by both statins more than 3 fold at 24 hours statin treatment. There were some differences between pitavastatin and atorvastatin. Pitavastatin reduced asparagines synthase and ST2 mRNAs to a greater extent than did atorvastatin.
Columns C and D of Table 1 indicate the top 5 genes most profoundly induced by statins. After 8 hours and 24 hours integrin β4 and thrombomodulin are induced more than 5 fold by both statins. At 24 hours, the thirdly induced gene by pitavastatin was Id-1, a type of helix-loop-helix transcriptional regulator (41) . Thromobomodulin is a cell surface anti-coagulant gly- Two enzymes concerned with intracellular processing of nucleotide second messengers, cGMP-stimulated 35-cyclic nucleotide phosphodiesterase (PDE2A), and CD39/ ATPDase mRNA, were induced transiently at 8 hours.
Expression levels of decay accelerating factor, an inhibitor of complement function and inflammation, and eNOS were induced. The induction of eNOS and the suppression of ET1 suggest that statins may reduce the vascular tone. This dose-dependent effect of pitavastatin was studied by RT-PCR (Fig. 2) .
(2) HCASMC Table 2 indicates the genes most profoundly affected in cultured HCASMC. Expression of thrombomodulin was induced more than 5 fold by both statin and the effect continued up to 24 hours. Another gene for anti-coagulation, urokinase inhibitor, also known as plasminogen activator inhibitor-2 (PAI-2)(45), was also induced. RhoA was a secondary induced gene at 8 hours by pitavastatin, which may be a compensatory reaction against the inhibition of Rho function by statin. Expression level of meningioma 1 (MN1), insulin-like growth factor binding protein 5 (IGFBP5), and CD24 were also induced more than 5 fold by both statins at 24 hours treatment.
Expression levels of the genes for cell cycle and growth were inhibited by both statins in HCASMC. Angiogenic inducer Cyr61 was suppressed most profoundly by pitavastatin at 8 hours. Cyclin B was most profoundly suppressed at 24 hours. Statins also suppressed the expression of genes concerned with cell growth and division including BDNF, ceramide glucosyltransferase, P55cdc, DNA polymerase delta subunit, thymidylate synthase and mitotic centromere-associated kinesin. Pitavastatin reduced cyclin B and P55cdc mRNAs to a greater extent than did atorvastatin. Table 3A summarizes the expression level of several insulin-like growth factor binding proteins (IGFBP) and bone morphogenic proteins (BMP) which were changed after statin treatment. Expression of IGFBP5, IGFBP6, BMP2, and BMP5 was induced. These genes were not induced in HUVEC or in Hep G2. In contrast, expression of IGFBP8 (connective tissue growth factor), which consists of an immediate early gene subfamily (46) , was markedly suppressed in both HCASMC and HUVEC.
The suppression of cyclin B and p55cdc suggest that the expression of other cell cycle related proteins may be affected by statins, and we checked the expression level of genes for cyclin and related proteins.
In being added to cyclin B, expression of cyclin Hand cyclin dependent kinase 4 was suppressed in HCASMC and to a lesser degree in HUVEC, but not in Hep G2 (Table  3B) .
(3) HepG2
In HepG2 cells, compared with HUVEC or HCASMC, statins did not indicate the prominent gene expression change (Table 4 ). There was no gene that changed more than 5 fold by both statins. At 24 hours, there were several genes induced by both statins more than 3 fold (Table  4D) . They are not directly related to coagulation, vascular tonus or other vascular functions. The genes most profoundly affected in HUVEC or HCASMC were not changed profoundly in Hep G2.
Discussion
DNA microarray analysis indicated that levels of many genes are induced or suppressed by statins in vascular cells. Adding to previously reported genes including (5) eNOS (8, 47) , ET-1, MCP-1, and PAI-1, the mRNA levels for many additional genes can be affected by statin treatment in HUVEC and/or HCASMC. These effects were not prominent in Hep G2 cells, suggesting the cell type specificity of these effects. One of the most clearly affected novel genes is PTX3. PTX3 is one of the long pentraxin family members like C-reactive protein and serum amyloid protein (48) . PTX3 can serve as a marker of inflammatory reactions involving the vessel wall (37) . The expression of PTX3 was observed in advanced atherosclerotic plaques (39) , and PTX3 played a role in thrombogenesis and ischemic vascular disease by increasing tissue factor expression (38) . Considering these reports, suppression of PTX3 expression by statin may reduce the risk of cardiovascular disease. Another important gene whose expression is significantly induced was thrombomodulin. Thrombomodulin is an endothelial cell surface glycoprotein that forms a 1:1 complex with thrombin and converts thrombin into a physiologic anticoagulant. We observed that statins increased the mRNA levels for trombomodulin in HCASMC and HUVEC. Careful consideration will be needed to interpret this data because several reports indicate that the plasma level of soluble thrombomodulin decreased during statin treatment (49) . The level of soluble plasma thrombomodulin is considered the indicator of endothelial cell damage. The increased expression of intact cell surface thrombomodulin by statins may be protective against clot formation in atherosclerotic patients. Further studies on the thrombomodulin protein in vascular cells will be necessary.
Adding to thrombomodulin, expression levels of several genes concerned with coagulation are affected by statins in vascular cells. Generally, statins upregulate the genes for anti-coagulant and profibrinolysis. However we found the expression level of urokinase inhibitor, also known as PAI-2, was induced in HCASMC. Previous papers reported that statins reduced the mRNA levels for PAI-1 in endothelial cells and plasma PAI-1 levels in hyperlipemic patients (9) . We checked the PAI-1 expression in our experiment condition by DNA chip and RT-PCR (Fig. 2) , and the reduction of PAI-1 mRNA level was confirmed. Recently several experimental results raise the question about the physiological function of PAI-2. PAI-2 belongs to the serin protease inhibitor superfamily and suppresses plasminogen activator in vitro (45) . But however, the analysis of PAI-2 knockout mice indicated that this gene is not required for development or survival (50) . Recent results suggested that PAI-2 may be related to cell migration. The implication of the induction of PAI-2 by statin in HCASMC remains to be clarified.
Taken together, the combinatorial effect including the induction of thrombomodulin, tPA and the suppression of PAI-1 and PTX3 indicate that statins seem to modu- BMP2A  96 211 216 33 192 170 <10 <10 <10 <10 <10 <10 <10 <10 <10 <10 <10 <10  AB000584 BMP5  39  45  95 34 252 170 688 225 270 285 196 184 861 971 601 1100 1107 1417  L27560  IGFBP5  42  28  23 12 168 127 <10 <10 <10 <10 <10 <10 <10 <10 <10 <10 <10 <10  M62402  IGFBP6  744 late the gene expression towards anti-coagulation and pro-fibrinolysis.
The combinatorial anti-atherosclerotic effect is a remarkable characteristic of statin. In HUVEC, statins induced mRNA for eNOS and reduced mRNA for ET-1. Statins again suppressed the vasoconstrictive factors and upregulated genes for vasodilators.
In this study, we identified many genes related to cell cycle and growth as targets for statin's effect. The mRNA for RhoA is induced profoundly. This result is of particular interest because statins are known to suppress the generation of geranylgeranyl pyrophophate which is important for the modification of Rho and also essential for its function. Previous reports indicated that the effect of statin against PAI-1 were reversed by mevalonate and geranylgeranyl pyrophosphate, but not by LDL cholesterol and farnesyl pyrophosphate (9) . The induction of mRNA for Rho A may be a cellular compensation mechanism for the reduction of Rho function.
Recently the anti-angiogenic effect of another potent statin, cerivastatin, through the suppression of p21waf1/ Cip1 expression has been reported (51) (52) (53) . In this study statins induced the mRNA level for p21Waf1/Cip1 in HCASMC (Table 3 B) . p21Waf1/Cip1 tightly binds to cyclin A, D1 and E and CDK2 (54) . It is a potent inhibitor of CDK2. A previous report suggests that the synthesis of geranylgeranyl pyrophosphate is activated during the G1/M transition, which leads to the enhanced modification of small G proteins and may promote G1/S phase transition. The induction of p21Waf1/Cip1 mRNA and the suppression of expression of cyclin B, H, CDK4 and p55cdc may be related to the inhibitory effect of statins in the growth of smooth muscle cells. Statins differ in their ability to reduce asparagines synthase, ST2, cyclin B and P55cdc (Table 1 , 2). In our previous paper, pitavastatin induced LDL receptor mRNA and upregulated LDL receptor function most effectively among statins in HepG2 cells (36) . The ability of statin to lower LDL cholesterol levels may be relevant to reduce these genes.
Statins can induce mRNA for several growth factors and their regulatory proteins, including IGFBP5. IGFBP5 binds IGFs and PAI-1 (55) , which leads to the inactivation of these proteins. Statins also induced BMP2A and 5 mRNA levels specifically in HCASMC. In contrast, the mRNA level for connective tissue growth factor (CTGF)/IGFBP8 was suppressed both in HUVEC and HCASMC. Although it has some structural similarities with IGFBPs, this CTGF indicated low affinity to IGF, and together with Cyr 61 they constitute an immediate early gene subfamily called CCN. The suppression of the expression of Cyr61, and CTGF/IGFBP8 adding to PTX-3 may be one of the important pathways suppressing the pro-inflammatory process in vascular cells. Two enzymes concerned with the intracellular processing of nucleotide second messengers, cGMP-stimulated 3'5'-cyclic PDE2A and CD39/ATPDase mRNA, were induced transiently at 8 hours. Recently, the reversal of thrombin-induced deactivation of CD39/ATPDase by statins in endothelial cells has been reported (56) . In that report, statins prevented the thrombin -induced downregulation of CD39/ATPDase expression in HUVEC. We found that without pathological stimulation, CD39/ ATPDase mRNA can be induced by statins. Compared with other phosphodiesterase, the physiological function of PDE2A remains uncertain. PDE1, 3, 4 and 5 mediate vasoconstriction and/or platelet aggregation. Recently it has been reported that PDE2A attenuate cAMP accumulation in adult rat cardiac fibroblast stimulated by IL-1β (57) . Statins may attenuate the pathological stimulation of endothelial cells by inducing these genes.
Comprehensive analysis of RNA expression profile in the vascular cells indicated the regulation of four groups of genes by statins. These include the genes concerned with vascular tone, coagulation, inflammation and cell growth. The precise mechanism by which statins regulate the expression level of these genes remains uncertain. Geranylgeranyl pyrophosphate metabolism and the successive inhibition of small G proteins may play an important role. It has been reported that not only human native LDL cholesterol but also isoprenoids prevent eNOS upregulation by statins (58, 59) . The mechanism of these pleiotropic effects by statins may be both in a cholesterol-dependent and cholesterol-independent manner. The induction of SREBP2 mRNA levels and the formation of a large protein complex called cofactor required for Sp1 activation/activator-recruited cofactor-L may also be involved. The promoter sequence of some of the newly identified target genes, PTX3 and thrombomodulin, have been extensively studied already and the studies about transcriptional regulation by statins will provide a molecular basis for the pleiotropic effect of statins.
